LJ International Inc. JADE 深 滬
等待開盤 09-09 09:30:00 美东时间
57.3611
+0.458
+0.80%
華盛通- 最 高57.3611
- 今 開56.9033
- 成交量 7股
- 最 低 57.3611
- 昨 收 56.9033
- 總市值 1720.83万
- 52周最高 57.3611
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 42.18
- 委 比 0.00%
- 總股本 30.00万
- 歷史最高 57.3611
- 量 比 0
- 振 幅 0.00%
- 歷史最低 42.18
- 每 手 1
- 風險率 3.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Jade Biosciences Starts Phase 1 Trial Of JADE101 Antibody For IgA Nephropathy, Eyes 2026 Data
Jade Biosciences, Inc. ("the Company" or "Jade"), (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has dosed the first
09-02 19:03
Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy
A clinical-stage biotechnology company, Jade Biosciences, has initiated a Phase 1 trial for JADE101, a monoclonal antibody targeting APRIL for IgAN treatment. JADE101 shows high binding affinity and potential for infrequent dosing. Mid-2026 interim data will guide dose selection based on biomarkers.
09-02 11:00
业聚医疗（6929.HK）：营收净利双增，全球化与创新双轮驱动
2025年，全球化依然是医疗器械行业发展的主旋律。而心血管介入领域的先行者——业聚医疗，凭借前瞻性的全球化布局，在地缘政治的复杂变局下，仍能深入超70个国家和地...
08-18 08:54
Jade Biosciences to Participate in Two Upcoming Investor Conferences
Jade Biosciences announced its participation in two upcoming investor conferences. CEO Tom Frohlich and CSO Andrew King will discuss the company's pipeline, including JADE101 for immunoglobulin A nephropathy, at the H.C. Wainwright Kidney Virtual Conference on July 14 and the Stifel Biotech Summer Summit on August 13. Both events will include fireside chats and one-on-one investor meetings. Jade is focused on developing best-in-class therapies fo...
07-08 11:00
Jade Biosciences Appoints Brad Dahms as Chief Financial Officer
Jade Biosciences, Inc., a biotech company focused on autoimmune diseases, has appointed Brad Dahms as its Chief Financial Officer. Dahms, with a strong track record in biotech finance and strategic leadership, joins Jade to support its growth, including advancing its lead candidate JADE101 for IgA nephropathy into clinical trials in 2025. His prior experience includes roles at IDRx, Theseus Pharmaceuticals, and Selecta Biosciences, where he led f...
07-01 11:00
Jade Road Investments Delays 2024 Annual Report
Jade Road Investments ( ($GB:JADE) ) has provided an announcement. Jade Road In...
07-01 03:46
Jade Biosciences Presents Detailed Preclinical Characterization Of JADE101 In Development For IgAN, Chronic Autoimmune Kidney Disease; First-In-Human Trial Expected To Begin H2 2025
Preclinical data highlighted JADE101's femtomolar APRIL binding affinity, extended non-human primate half-life of approximately 27 days, and sustained IgA suppressionIn non-human primates, JADE101 showed a differentiated
06-09 19:03
Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress
Jade Biosciences, Inc. announced that new preclinical data on JADE101, its anti-APRIL monoclonal antibody for treating IgA nephropathy, will be presented at the 62nd ERA Congress in Vienna on June 6, 2025. The company will host a conference call and webcast on June 9, 2025, to discuss the data. JADE101 targets APRIL to reduce pathogenic IgA, decrease proteinuria, and preserve kidney function. A replay of the webcast will be available on the compa...
06-02 11:00
Jade Road Investments Awaits Closure of £1 Million Subscription Agreement
Jade Road Investments ( ($GB:JADE) ) just unveiled an announcement. Jade Road I...
05-27 23:07
Jade Road Investments Awaits Fund Receipt for Subscription Agreement
An announcement from Jade Road Investments ( ($GB:JADE) ) is now available. Jad...
05-06 22:02
